Quantum Sky develops advanced artificial intelligence solutions leveraging quantum computing principles. The company focuses on creating next-generation AI models capable of handling complex computational tasks. Their offerings aim to enhance processing speed and analytical depth for enterprise applications.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional biotechnology is limited by its reliance on existing biological molecules, hindering the development of novel solutions for challenges like aging, climate change, and sustainable energy. The current approach of tweaking existing molecules restricts the full potential of biotechnology.
Solution
Quantum Sky has developed the SkyEngine, an AI platform that uses Generative AI (GAI) and Quantum Mechanics AI (QMAI) to design and optimize biomachines, including proteins and RNAs. The SkyEngine expands the alphabet of building blocks to over 400 amino acids and non-canonical bases, enabling the creation of novel biomolecules. This technology facilitates the rapid design of CRISPR-Cas proteins and RNA editing tools, which can be applied in diagnostics and therapeutics. The SkyEngine's architecture allows for unified implementation on both proteins and RNAs, generating interactive models that can answer key questions such as ligand binding and working pH.
Target Audience
The primary customers are companies working on genome editing, RNA editing, and delivery systems for nucleic acid medicines.
Features
- AI engine integrating both Generative AI (GAI) and Quantum Mechanics AI (QMAI)
- Expanded alphabet of over 400 amino acids and non-canonical bases for building proteins and RNAs
- Generates interactive models that can answer key questions such as ligand binding and working pH
- Facilitates the creation of de novo-designed CRISPR-Cas proteins
- Enables the development of RNA editing pipelines
- Achieves over 10 million times acceleration using QMAI compared to state-of-the-art models
- Requires only a few examples to generate working de novo proteins